| Literature DB >> 35602364 |
Bevinahalli Nanjegowda Raveesh1,2, Ravindra Neelakanthappa Munoli3, Guru S Gowda4.
Abstract
Entities:
Year: 2022 PMID: 35602364 PMCID: PMC9122159 DOI: 10.4103/indianjpsychiatry.indianjpsychiatry_22_22
Source DB: PubMed Journal: Indian J Psychiatry ISSN: 0019-5545 Impact factor: 2.983
Component behaviours of agitation
| Nonaggressive behaviors | Aggressive behaviors |
|---|---|
| Restlessness (akathisia, fidgeting) | Physical |
| Wandering | Combativeness, punching walls |
| Loud, excited speech | Throwing or grabbing objects, destroying items |
| Pacing or frequently changing body positions | Clenching hands into fists, posturing |
| Inappropriate behavior (disrobing, intrusive, repetitive questioning) | Self-injury (repeatedly banging one’s head) |
| Verbal | |
| Cursing | |
| Screaming |
Signs for preliminary identification of agitation
| Inability to stay calm or still |
| Motor and verbal hyperactivity and hyperresponsiveness |
| Emotional tension |
| Difficulties in communication |
Etiology of agitation
| Primary psychiatric conditions | Medical conditions |
|---|---|
| Delirium | Head injury |
| Dementia | CNS infections- meningitis, encephalitis |
| Substance intoxication (alcohol, cannabis, cocaine, stimulants, hallucinogens, inhalants) | Encephalopathies (hepatic, renal, etc.) |
| Substance withdrawal (alcohol delirium) | Brain tumors/metastases |
| Schizophrenia | Stroke |
| Bipolar affective disorder | Wernicke-korsakoff’s psychosis |
| Agitated depression | Metabolic abnormalities (electrolytes, glucose, calcium, etc.) |
| Anxiety disorder | Hypoxia |
| Personality disorder-antisocial | Toxins/poisoning |
| Autism/intellectual disability | Hormonal (thyroid dysfunction) |
| Posttraumatic stress disorder | Seizure (postictal state) |
| Adverse effects/toxicity of mediations |
CNS – Central nervous system
The signs of impending violence[10]
| Provocative behavior |
| Angry demeanor, fixed gaze, avoidance of gaze, hostile facial expression |
| Loud, excited, aggressive speech |
| Tense posturing (e.g., gripping arm rails tightly, clenching fists) |
| Pacing or frequently changing body position |
| Aggressive acts (e.g., pounding walls, throwing objects, hitting oneself) |
| Behaviour of looking for an escape |
| Physical signs of stress (e.g., hyperventilation, sweating, tremor) |
Critical information which must be part of the history of presenting illness
| Timing of agitation |
| Nature of agitation |
| Concomitant substance use |
| Medication details: changes, new medicines, stopped any medicine |
| Noncompliance to medications |
| Other medical conditions |
Common and potentially life-threatening aetiologies of the acutely agitated patient[16]
| Toxicological | Metabolic |
| Alcohol intoxication or withdrawal | Hypoglycemia |
| Stimulant intoxication | Hyperglycemia/diabetic ketoacidosis |
| Other drugs or drug reactions | Hypoxia |
| Neurologic | Hyper/hyponatremia |
| Stroke | Other medical conditions |
| Intracranial lesion (e.g., hemorrhage, tumor) | Hyperthyroidism/thyroid storm |
| CNS infection | Shock syndromes |
| Seizure disorder | AIDS |
| Dementia | Hypothermia or hyperthermia |
| Psychiatric | |
| Psychosis | |
| Schizophrenia | |
| Paranoid delusional disorder | |
| Personality disorder | |
| Antisocial behavior |
CNS – Central nervous system; AIDS – Acquired immune deficiency syndrome
Figure 1SMART medical clearance form
Figure 2Initial assessment of agitated patient. (*) - ICU - Intensive care unit, HDU - High dependency unit
Figure 3Diagnostic evaluation
General recommendations in managing agitation
| Initial attempts should identify the most likely cause of agitation and establish a provisional diagnosis and specific medication for the diagnosed cause/condition. Medications as restraint can be discouraged initially before arriving at any provisional diagnosis |
| Nonpharmacologic methods of interventions should be considered. Environmental modifications to reduce stimulation (low lighting, quiet room) and verbal de-escalation have to be considered, if possible, before medications |
| Medications sold calm the patient rather than induce sleep |
| Patient should be kept in the loop of proceedings, even if the patient is agitated. E.g., convey the need for restraints, choice of medication, selection of room/ward, check for preference of route of medicine administration, duration of conditions, etc. |
| If the patient is cooperative to take oral medicines, then oral medication can be preferred based on resources available for managing any acute exacerbation |
Communication/behavioural interventions[18]
| Nonverbal | Verbal |
|---|---|
| Maintain a safe distance | Speak in a calm, more transparent tone |
| Maintain a neutral posture | Personalize yourself |
| Do not stare; the eye contact should convey sincerity | Avoid confrontation; offer to solve the problem |
| Do not touch the patient | |
| Stay at the same height as the patient | |
| Avoid any sudden movements | |
| Aligning goals of care | Monitoring intervention progress |
| Acknowledge the patient’s grievance | Be acutely aware of progress |
| Acknowledge the patient’s frustration | Know when to disengage |
| Shift the focus to a discussion of how to solve the problem | Do not insist on having the last word |
| Emphasize common ground | |
| Focus on the big picture | |
| Find ways to make small concessions |
Figure 4Algorithm to use medical restraint
Indications and contraindications for medical restraints and seclusion
| Indications | Contraindications |
|---|---|
| Risk of imminent harm to self | Unstable medical condition |
| Risk of imminent harm to others | Severe drug reaction or overdose |
| Serious destruction to the environment | Punishment |
| Staff convenience | |
| Patient’s voluntary reasonable request | If experienced by the patient as positive |
| Decrease sensory overstimulation* | reinforcement for violence or disruptive behavior |
| Only for seclusion* |
*Only for seclusion
Adverse outcomes related to medical restraints
| Patient-related adverse events | Staff-related adverse events |
|---|---|
| Asphyxiation | Spit upon |
| Choking/aspiration | Fracture or skin injury |
| Dehydration | Eye injury |
| Joint injuries | Permanent disability |
| Blunt chest trauma | Adverse emotional reactions (e.g., sadness, guilt, self-reproach, retribution) |
| Skin problems (e.g., Bruising) | |
| Cardiac arrest/death | |
| Rhabdomyolysis | |
| Thrombosis (e.g., PE, DVT) | |
| Escaping restraint | |
| Escalating agitation | |
| Re-traumatization | |
| Emotional distress | |
| Feelings of humiliation, fear, dehumanization, isolation, being ignored |
PE – Pulmonary embolism; DVT – Deep vein thrombosis
Factors to be considered before the physical restraints
| • What are the objectives of physical restraint? |
| • What are the risks associated with particular physical restraint? |
| • Management plan of specific anticipated risks associated with the particular restraint plan |
| • Consensus about the exact timing of using a specific physical restraint |
| • Patient-specific risk factors: age, gender, degree of cooperation, possible intoxication, any medications given, presence of cardiovascular, respiratory, neurological, or musculoskeletal disorders |
| • Any specific risk factors that may increase the patient’s risk of harm during restraint? |
| • Vulnerability to significant psychological trauma, especially for minors and the elderly |
| • Any cultural connotations |
| • Availability of emergency medicines, oxygen, required medical equipment |
Instructions to the staff carrying physical restraint
| Before physical restraint |
| Know the steps and plan clearly |
| Adheres to the plan discussed to execute the use of physical restraint safely. Ensure that mechanical and postural factors should not interfere in breathing or circulation: e.g., to avoid prone restraint or any other position where the patient’s head or trunk is bent towards their knees |
| During the physical restraint |
| Physical force used should be as per the necessity and in a reasonable manner |
| To avoid excessive physical force or verbal aggression |
| Ensure and monitor ABC all the time: Airway, Breathing, Circulation |
| Consciousness and body alignment have to be monitored by the clinician |
| Do not put direct pressure on the neck, chest/thorax, back, or pelvic area |
| Nurse/resident doctors/duty doctors must observe for physical or mental distress indications and ensure that clinical concerns are timely and appropriately escalated and appropriate intervention is provided |
| Specifically, monitor patients who have received intramuscular or intravenous medication within an hour before (or during) the use of physical restraint |
| On period reviews, if necessary, physical restraint positions can be changed as per the need and safety of the patient |
| Discontinue physical restraint as soon as it is no longer required |
| Risk assessment of continuing or discontinuing the physical restraint needs to be continuously assessed and balanced |
| Postrestraint debriefing |
| After the physical restraint ends and the patient is cooperative, a debriefing session with the patient and the patient’s caretakers must be conducted. This is done |
| To ensure open discussion about the events that led to the use of physical restraint |
| To discuss the patient’s experience of events and physical restraint |
| To allow the patient to clarify any doubts or seek more details |
| To provide an opportunity to identify the risk factors and plan strategies for the prevention of the need for physical restraint |
APPENDIX
| Appendix 1 |
|---|
| Medical restraint flowsheet |
| I. Patient’s details |
| Name: Age: Gender: Male/female/others Hosp. No. |
| II. Clinician’s order |
| Name: Dr. Date: Time: |
| a. Doctor’s Orders (orders must be renewed every 12–24 h based on the practice) |
| 1. |
| 2. |
| 3. |
| b. Initial Order |
| Start: Date/time |
| End: Date/time |
| c. Repeat order |
| Start: Date/time |
| End: Date/time |
| III. Alternatives attempted before initiation of medical restraints (check all that apply) |
| □Re-orient patient to time/date/place/person and/or situation |
| □Move patient closer to the nurses’ station |
| □Conceal lines/tubes/devices |
| □Minimize stimulation |
| □Reevaluate need for lines and tubes |
| □Appropriate diversional activities |
| □Repositioning |
| □Pain and sedation intervention |
| □Other |
| IV. Indication for using medical restraints |
| □Pulling lines |
| □Pulling tubes |
| □Removal of equipment |
| □Removal of dressing |
| □Inability to respond to direct requests or follow instructions |
| □Other |
| V. Type and details of medical restraints applied (Tick all that applies) |
| Wrists: Both/right only/left only |
| Legs: Both//right only/left only |
| Gloves/mittens: Both//right only/Left only |
| Waist Belt: Yes/No |
| Side railings: Yes/No |
| VI. Psycho-education of the patient |
| a. Informed the patient about the need and alternatives for medical restraints. Yes/No |
| b. Periodically patient has explained the behavior required to discontinue the restraint until an understanding was evidenced. Yes/No |
| Nurse’s name and sign Date and time |
| Doctor’s name and sign Date and time |
Medications used in managing agitation
| Initial dose (mg) | Tmax* (min) | Can repeat (h) | Maximum dose (per 24 h), mg | |
|---|---|---|---|---|
| Oral | ||||
| Risperidone | 2 | 1 h | 2 | 6 |
| Olanzapine | 5-10 | 6 h | 2 | 20 |
| Haloperidol | 5 | 30-60 | 15 m | 20 |
| Lorazepam | 2 | 20-30 | 2 | 12 |
| IM | ||||
| Olanzapine | 10 | 15-45 | 20 m | 30 |
| Haloperidol | 5 | 30-60 | 15 m | 20 |
| Lorazepam | 2 | 20-30 | 2 | 12 |
| Ziprasidone | 10-20 | 15 | 10 mg q 2 h | 40 |
| 20 mg q 4 h | ||||
| >Aripiprazole | 9.75 | 1 h | 2 | 30 |
| IV | ||||
| Haloperidol | 5 | Immediate | 4 | 10 |
| Lorazepam | 2 | Immediate | 2 | 12 |
Maximum doses can vary depending on the outcome. q 2 h – Every 2 hours; q 4 h – Every 4 hours, IM – Intramuscular; IV – Intravenous
Figure 5Pharmacological intervention
Use of benzodiazepines and typical antipsychotics in agitation
| Medication class | Medication | Dosing | Side effects/considerations |
|---|---|---|---|
| Benzodiazepine | Alprazolam | Only available PO | Paradoxical reactions can be seen in character-disordered patients and can worsen symptoms in the elderly |
| Initial dose is 0.5-4 mg/day | |||
| Diazepam | PO, IM, IV | Calming/sedating effect with rapid onset | |
| Start at 5 mg | Use cautiously with elderly patients because of the long half-life | ||
| Lorazepam | PO, SL, IM, IV | There are no active metabolites; therefore, there is a small risk of drug accumulation | |
| Start at 1 mg, moderate half-life (10-20 h) | Metabolized only via glucuronidation; therefore, it can be used in most patients with impaired hepatic function | ||
| Drug of choice within this class due to the moderately long half-life | |||
| Typical antipsychotics | Haloperidol | PO, IM, IV | High-potency neuroleptic with favorable side-effect profile and cardiopulmonary safety |
| Start at 5-10 mg IM, IV | IV form less likely to cause EPS | ||
| ECG monitoring is needed to assess torsades de pointes or QTc prolongation | |||
| NMS risk increases in poorly hydrated, restrained, and kept in poorly aerated rooms while given large doses of antipsychotics | |||
| Frequent vital sign checks and testing for muscular rigidity are recommended | |||
| Can cause hypotension |
Adapted from Allen M, Currier G, Carpenter D: The expert consensus guideline series: treatment of behavioral emergencies, J Psychiatr Pract 11:1-112, 2005. CVD – Cardiovascular disorder; ECG – Electrocardiogram; EPS – Extrapyramidal symptoms; IM – Intramuscular; IV – Intravenous; NMS – Neuroleptic malignant syndrome; PO – Per os (by mouth, orally); SL – Sublingual; PR – Per rectum
Use of benzodiazepines and typical antipsychotics in agitation
| Medication class | Medication | Dosing | Side effects/considerations |
|---|---|---|---|
| Atypical antipsychotics | Risperidone | PO, OTD | No IM form is available |
| Starting dose 0.5-2 mg acutely | Offers calming effect with the treatment of the underlying condition | ||
| Orthostatic hypotension with reflex tachycardia | |||
| Increased risk of stroke in the elderly with CVD | |||
| Olanzapine | PO, OTD, IM | Useful in patients with poor reaction to haloperidol | |
| Starting dose 2.5-5 mg, maximum 30 mg/24 h with doses 2-4 h apart | Calming medication with the treatment of the underlying disorder | ||
| Aripiprazole | PO, OTD | Akathisia risk | |
| Starting PO dose 5-10 mg, maximum 30 mg/day (currently IM formulation only for extended-release maintenance therapy) | Less sedating than other medications | ||
| Increased risk of stroke in the elderly | |||
| Good choice for patients with QT interval prolongation | |||
| Combinations | Haloperidol, lorazepam, diphenhydramine, or benzatropine | 5 mg IM, 2 mg IM, 50 mg IM, 1 mg IM | Most commonly used in the acute setting |
| Young athletic men are at increased risk for dystonia | |||
| Akathisia must be considered if agitation increases after administration |
PO – Per os (by mouth, orally); OTD – Orally disintegrating tablet; IM – Intramuscular; CVD – Cardiovascular disorder
Factors to be considered while choosing medications
| • Patient’s details: Age, gender, comorbid medical conditions, substance use, allergies |
| • Agitation details: Cause, presentation |
| • Pharmacological considerations: Route of administration, rapidity of action, duration of action, adverse effects and interaction with other medications, past good response to any particular psychotropic |
| • Monitoring facilities: Airway, breathing, and circulation monitoring facilities; crash cart for any medical emergency, availability of ICU and ventilator |
| • Patient’s preference of route of administration |
| • Route of administration |
| • Oral: Tablets or syrups can be preferred if the patient accepts |
| • IM: Helps in rapid elevation of drug plasma levels and faster onset of action, leading to an immediate reduction in agitation |
| • IV administration should be preferred when rapid restraint is essential |
| • IM – Intramuscular; IV – Intravenous; ICU – Intensive care units |
Medical restraint flow sheet contd…
| VII. Patient’s monitoring chart |
| In the first hour, observation checks are done every 15 min, then hourly |
| •15 min: Time_______ Behavior (**See Key)___________ Initials____________ |
| •30 min: Time_______ Behavior (**See Key)___________ Initials____________ |
| •45 min: Time_______ Behavior (**See Key)___________ Initials____________ |
| •60 min: Time_______ Behavior (**See Key)___________ Initials____________ |
| Time (hours) | 7 | 8 | 9 | 10 | 11 | 12 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 1 | 2 | 3 | 4 | 5 | 7 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Observation check | ||||||||||||||||||||||||
| (**See Key) Q1h | ||||||||||||||||||||||||
| Circulation/skin check | ||||||||||||||||||||||||
| Q2h | ||||||||||||||||||||||||
| Food/fluids | ||||||||||||||||||||||||
| Q2h | ||||||||||||||||||||||||
| Elimination (or F for Foley in place) | ||||||||||||||||||||||||
| Q2h | ||||||||||||||||||||||||
| Range of Motion | ||||||||||||||||||||||||
| Q2h | ||||||||||||||||||||||||
| Change in type or number of | ||||||||||||||||||||||||
| Staff initials | ||||||||||||||||||||||||
| Key: *Restraints | **Observed Behavior (May use more than one) | |||||||||||||||||||||||
| NC=No change | CF – Confused; AG – Agitated; VA – Verbally abusive; TF – Tearful; JC – Hallucination; DL – Delusional; A – Patient asleep; SD – Sedated; SB – Subdued; CA – Calm; CO – Cooperative; O – Other | |||||||||||||||||||||||
| ↑3=Increase to 3pt | ||||||||||||||||||||||||
| ↑4=Increase to 4pt | ||||||||||||||||||||||||
| ↓1=Decrease to 1pt | ||||||||||||||||||||||||
| ↓2=Decrease to 2pt | ||||||||||||||||||||||||
| ↓3=Decrease to 2pt |
Table investigations and rationale
| Investigation | Rationale |
|---|---|
| Haemogram: Hb, TC, DC, ESR, Platelets, Indices | To evaluate infective etiology, anemia |
| RFT: Urea, creatinine, sodium, potassium | To evaluate renal causes and electrolyte imbalances |
| LFT: Total/direct bilirubin, AST, ALT, ALP, GGT, total protein, albumin, globulin, A/G ratio | To evaluate hepatic causes, acute/chronic liver disease, hepatic encephalopathy |
| TFT: T3, T4, TSH | To evaluate thyroid etiology |
| Sugars: RBS, FBS, PPBS, HBA1C | Hypoglycemia/hyperglycemia related causes |
| Urine complete analysis, microscopy, and urine drug screening | For detection of substances |
| Serum toxicology | Based on the history |
| Drug levels | If on valproic acid, lithium, carbamazepine, phenytoin, and toxicity is suspected |
| Ultrasound abdomen and pelvis | Based on history and indication: Blunt trauma abdomen |
| 12-Lead ECG | For cardiac causes and cardiac monitoring for medication-related changes |
| CT/MRI brain/part of the interest | As per the history and indication |
| Lumbar puncture and EEG | As per the indication |
Hb – Hemoglobin; HBA1C – Hb A1C; AST – Aspartate transaminase; ALT – Alanine aminotransferase; FBS – Fasting blood sugar; CT – Computed tomography; MRI – Magnetic resonance imagin
Association for Emergency Psychiatry Recommendations
| Situation | Preferences |
|---|---|
| Undifferentiated agitation/suspected intoxication with stimulant or withdrawal from alcohol/benzodiazepine | Oral benzodiazepines (e.g., lorazepam 1-2 mg) |
| Parenteral benzodiazepines (e.g., lorazepam 1-2 mg IM or IV) | |
| Acute intoxication with CNS depressant (e.g., alcohol) | Avoid benzodiazepine if possible |
| Oral 1st generation antipsychotic (e.g., haloperidol 2-10 mg) | |
| Parenteral 1st generation antipsychotic (e.g., haloperidol 2-10 mg IM) | |
| Delirium (not associated with alcohol or benzodiazepine withdrawal) | Oral 2nd generation antipsychotic (e.g., risperidone 2 mg, olanzapine 5-10 mg) |
| Oral 1st generation antipsychotic (e.g., low dose haloperidol) | |
| Parenteral 2nd generation antipsychotic (e.g., olanzapine 10 mg IM) | |
| Parenteral 1st generation antipsychotic (e.g., haloperidol low dose IM or IV) | |
| Schizophrenia or mania | Oral 2nd generation antipsychotic alone (e.g., risperidone 2 mg, olanzapine 5-10 mg) |
| Oral 1st generation antipsychotic (e.g., haloperidol 2-10 mg with benzodiazepine) | |
| Parenteral 2nd generation antipsychotic (e.g., olanzapine 10 mg IM) | |
| Parenteral 1st generation antipsychotic (e.g., haloperidol 2-10 mg IM) along with benzodiazepine (e.g., lorazepam 1-2 mg) |
CNS – Central nervous system; IV – Intravenous
Salient pharmacological features of benzodiazepines
| Class/molecule | Pharmacological features |
|---|---|
| Benzodiazepines | Act by facilitating the activity of GABA, which is a major inhibitory neurotransmitter |
| Therapeutic effects due to decreased arousal | |
| Target symptom anxiety | |
| Can be used alone or in combination with antipsychotics | |
| Preferred in a patient in whom agitation is secondary to alcohol or sedative withdrawal | |
| Side effects to consider | |
| Excessive sedation; added sedation when combined with CNS depressant | |
| Respiratory depression; to avoid in patients with risk for CO2 retention | |
| Paradoxical disinhibition in high doses in patients with structural brain damage, mental retardation, or dementia | |
| Ataxia | |
| Typical antipsychotics (FGA) | Dopamine antagonist |
| Advantageous effects: as antipsychotic and for agitation | |
| Preferred in acute agitation | |
| Low potency FGA: Not recommended | |
| High potency FGA (haloperidol): virtually no anticholinergic properties, little risk of hypotension, no respiratory depression, can be given IV, the onset of action is within 30 min and lasts up to 12-24 h | |
| Side effects to consider | |
| EPS | |
| Neuroleptic Malignant Syndrome (NMS) | |
| Dystonia | |
| Akathisia | |
| Parkinson-like effects | |
| QTc prolongation | |
| May lower the seizure threshold | |
| Atypical antipsychotics (SGA) | Broader spectrum of response |
| Different side effect profile | |
| Fewer EPS and akathisia | |
| QTc concern remains | |
| Metabolic syndrome on prolonged use | |
| Olanzapine | |
| IM dose range of 5-10 mg | |
| Maximum of 30 mg/day | |
| 15-45 min until peak plasma concentration | |
| 21-54 h elimination half-life | |
| Oral dose range 5-10 mg and flexible-dose up to 40 mg/day | |
| Risperidone | |
| 1–6 mg PO or ODT | |
| Oral risperidone concentrate 2 mg+oral lorazepam 2 mg equivalent to IM haloperidol 5mg+IM lorazepam 2 mg | |
| Oral risperidone 2 mg equally effective as oral haloperidol 5 mg | |
| Risk of EPS | |
| Aripiprazole | |
| Partial dopamine agonist | |
| Oral aripiprazole 15 mg as effective as oral olanzapine 20 mg | |
| Low risk for QT interval prolongation (<1%) | |
| Quetiapine | |
| 25 mg onwards up to 400 mg | |
| 1–3 h to peak plasma concentrations | |
| Shallow risk of EPS | |
| Sedation and orthostasis are side effects |
FGA – First generation antipsychotics; EPS – Extrapyramidal symptoms; SGA – Second generation antipsychotics; CNS – Central nervous system; IV – Intravenous